Research programme: antibody-conjugated doxorubicin liposomal - NanoSmart/NanoValent

Drug Profile

Research programme: antibody-conjugated doxorubicin liposomal - NanoSmart/NanoValent

Alternative Names: ANA-conjugated doxorubicin liposomal - NanoSmart/NanoValent; Anti-nuclear antibody-conjugated doxorubicin liposomal - NanoSmart/NanoValent; Dox-anti-CD19; Dox-anti-CD99; Doxorubicin liposomal - NanoSmart/NanoValent; NV101 NanoValent; NV102; NV103

Latest Information Update: 28 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NanoSmart Pharmaceuticals; NanoValent Pharmaceuticals
  • Class Anthracyclines; Doxorubicins; Immunoconjugates; Small molecules
  • Mechanism of Action CD antigen inhibitors; DNA intercalators; Reactive oxygen species stimulants; RNA synthesis inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ewing's sarcoma
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Acute myeloid leukaemia; Ewing's sarcoma; Precursor cell lymphoblastic leukaemia-lymphoma
  • No development reported Ovarian cancer; Solid tumours

Most Recent Events

  • 28 May 2018 No recent reports of development identified for research development in Ovarian-cancer in USA
  • 28 May 2018 No recent reports of development identified for research development in Solid-tumours in USA
  • 17 Nov 2015 Preclinical trials in Acute lymphoblastic leukaemia in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top